利格列汀对2型糖尿病合并心肾疾病患者认知功能的影响
CARMELINA-COG是CARMELINA心血管结局试验的认知亚研究,纳入1545例2型糖尿病合并心肾疾病患者,随机接受利格列汀5 mg每日一次或安慰剂。中位治疗2.5年期间,加速性认知下降发生率利格列汀组28.4%、安慰剂组29.3%(OR 0.96,95%CI 0.77–1.19),亚组与绝对认知变化均一致,提示利格列汀未改善认知下降。
要点
- 利格列汀5 mg每日一次未降低2型糖尿病合并心肾疾病患者的加速性认知下降风险。
- 加速性认知下降发生率28.4%对29.3%,OR 0.96(95%CI 0.77–1.19)。
- 各基线特征亚组及绝对认知评分变化在两组间相似。
核心结论
- 在2型糖尿病合并心肾疾病患者中,利格列汀治疗2.5年未调节认知下降。
研究设计与样本
- CARMELINA-COG为CARMELINA(NCT01897532)的认知亚研究,随机1:1接受利格列汀5 mg每日一次或安慰剂加标准治疗。
- 亚研究纳入1545例,平均年龄68±8岁,基线MMSE 28.3±1.7,eGFR 52±23 mL/min/1.73 m2,HbA1c 7.8±0.9%(61.4±10.1 mmol/mol)。
- 主要认知结局为治疗结束时加速性认知下降,定义为MMSE或注意力与执行功能复合测量回归指数评分≤第16百分位,在基线MMSE≥24者中分析。
主要发现
- 中位治疗2.5年,加速性认知下降发生率利格列汀组28.4%、安慰剂组29.3%(OR 0.96,95%CI 0.77–1.19)。
- 按基线特征各亚组效果一致,两组绝对认知表现变化亦相似。
临床怎么用
- 对于2型糖尿病合并心肾疾病患者,不应以改善认知为目的事先选用利格列汀。
- 认知功能下降的筛查与管理仍需按常规综合措施进行。
局限性
- 认知亚研究仅纳入1545例,中位随访2.5年,对长期认知结局的推断受限。
- 原文未报告亚研究的其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes is associated with cognitive dysfunction and an increased dementia risk, particularly in individuals with concomitant cardiovascular and/or kidney disease. Incretin therapies may modulate this risk via glycemic and nonglycemic pathways. We explored if the dipeptidyl peptidase 4 inhibitor linagliptin could prevent cognitive decline in people with type 2 diabetes with cardiorenal disease. RESEARCH DESIGN AND METHODS: The CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA)-COG substudy was an integral part of CARMELINA (NCT01897532) that randomized participants with cardiorenal disease to linagliptin 5 mg or placebo once daily (1:1), in addition to standard of care. The primary cognitive outcome was the occurrence of accelerated cognitive decline at the end of treatment, defined as a regression-based index score ≤16th percentile on the Mini-Mental State Examination (MMSE) or a composite measure of attention and executive functioning and analyzed in participants with a baseline MMSE ≥24. Effects across subgroups by baseline factors, as well as absolute cognitive changes, were also assessed. RESULTS: Of the 6,979 participants in CARMELINA, CARMELINA-COG included 1,545 (mean ± SD age, 68 ± 8 years; MMSE, 28.3 ± 1.7; estimated glomerular filtration rate, 52 ± 23 mL/min/1.73 m2; and HbA1c, 7.8 ± 0.9% [61.4 ± 10.1 mmol/mol]). Over a median treatment duration of 2.5 years, accelerated cognitive decline occurred in 28.4% (linagliptin) vs. 29.3% (placebo) (odds ratio 0.96 [95% CI 0.77, 1.19]). Consistent effects were observed across subgroups by baseline characteristics. Absolute cognitive performance changes were also similar between treatment groups. CONCLUSIONS: In a large international cardiovascular outcome trial in people with type 2 diabetes and cardiorenal disease, linagliptin did not modulate cognitive decline over 2.5 years.
引用
- Biessels GJ, Verhagen C, Janssen J, et al. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care. 2019. PMID: 31399442. doi:10.2337/dc19-0783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。